サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1301075

乳がん治療薬の市場規模・シェア・動向分析レポート：治療法別（標的療法、ホルモン療法）、流通チャネル別（病院薬局、小売薬局）、がんタイプ別（ホルモン受容体、HER2+）、セグメント別予測、2023年～2030年

Breast Cancer Drugs Market Size, Share & Trends Analysis Report By Therapy (Targeted, Hormonal), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), By Cancer Type (Hormone Receptor, HER2+), And Segment Forecasts, 2023 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 180 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
乳がん治療薬の市場規模・シェア・動向分析レポート：治療法別（標的療法、ホルモン療法）、流通チャネル別（病院薬局、小売薬局）、がんタイプ別（ホルモン受容体、HER2+）、セグメント別予測、2023年～2030年
出版日: 2023年06月19日
発行: Grand View Research
ページ情報: 英文 180 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

乳がん治療薬市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界の乳がん治療薬市場規模は2023年から2030年にかけてCAGR 9.09%で成長し、2030年には586億9,000万米ドルに達すると予測されています。

この成長の主な要因は、疾患有病率の上昇、研究開発投資の増加、著名企業による取り組みです。さらに、遺伝子構成に基づいて個々の患者に合わせた治療を行う個別化医療の動向が、市場の成長を促進しています。ゲノミクスと分子生物学の進歩により、従来の化学療法よりも効果が高く副作用の少ない標的療法が開発されています。世界中の政府が新薬や治療法の研究開発に投資しています。例えば、米国国立がん研究所は、いくつかの研究機関を設立しています。

例えば、米国国立がん研究所は、新薬の開発や既存の治療法の有効性を向上させるための研究プログラムをいくつか立ち上げています。同様に、オーストラリア政府は2023年1月、女性を対象とした治療法の開発に1,601万米ドルを投資すると発表しました。この投資は、National Health and Medical Research Councilによる助成金プログラムを通じて、乳がん研究を含む23のプロジェクトに資金提供される予定です。非営利団体の参加が増加していることは、市場の成長を促進すると予想されます。例えば、2022年6月、乳がん団体であるSusan G. Komenは、26の学術機関における約48の研究プロジェクトを支援するために2,100万米ドルを受け取ると発表しました。資金の大半は侵攻性乳がんの調査に割り当てられ、次いで臨床試験や格差解消のための研究が行われます。

さらに、乳がん患者は免疫力の低下によりCOVID-19による合併症のリスクが高まるため、パンデミックの影響を受けています。その結果、多くの患者が治療の延期やキャンセルを余儀なくされ、薬剤の需要に影響を与えました。さらに、パンデミックの経済的影響も市場に影響を与えました。雇用の喪失や所得水準の低下は、医薬品を購入する余裕に影響を与えました。その結果、製品需要が減少し、市場に短期的・中期的な影響を及ぼしました。薬価は市場に大きな影響を与えます。薬価が高ければ使用が制限され、需要に影響を及ぼす可能性がある一方、薬価が低ければ入手しやすくなり、需要が高まる可能性があります。したがって、利害関係者は、手頃な価格の薬剤の必要性と、治療選択肢を改善するための継続的な研究開発の必要性とのバランスを取る必要があります。

乳がん治療薬市場レポートハイライト

  • 免疫療法タイプは、2022年に市場で最も急成長した治療分野の1つです。免疫療法は、患者の免疫系を刺激してがん細胞を認識・攻撃させることで効果を発揮します。このアプローチは、乳がんを含む様々なタイプで有望な結果を示しています。
  • タイプ別では、ホルモン受容体セグメントが2022年の市場シェアの大半を占めました。ホルモン受容体陽性乳がんは、最も一般的なサブタイプです。そのため、ホルモン療法薬が治療の中心となっています。
  • 病院薬局の流通チャネル・セグメントが2022年に最大のシェアを占めました。病院薬局では、小売薬局やその他のチャネルと比較して、幅広い専門的な医薬品や治療法を入手できることが多いです。
  • 乳がんの有病率の増加、高いヘルスケア支出、継続的な研究開発活動により、北米が2022年の世界業界において圧倒的な地位を占めています。

目次

第1章 調査手法と範囲

  • 市場セグメンテーション
  • 市場の定義と目的
  • 調査手法
  • 情報調達
    • 購入したデータベース
    • Gvrの内部データベース
    • 二次情報
    • 1次調査
  • 情報またはデータ分析
    • データ分析モデル
  • 市場の形成と検証
  • モデル詳細
    • 商品フロー分析
  • 二次情報のリスト
  • 略語のリスト
  • 一次情報のリスト

第2章 エグゼクティブサマリー

  • 市場スナップショット
  • 治療法とがんタイプのスナップショット
  • 流通チャネルのスナップショット
  • 競合情勢のスナップショット

第3章 市場変数、動向、および範囲

  • 市場セグメンテーションと範囲
  • 市場系統の見通し
    • 親市場の見通し
    • 関連/補助的な市場見通し
  • 市場動向と展望
  • 市場力学
    • 世界中でがんの発生率と有病率が増加
    • 研究開発への多額の投資
    • がんの生物学と薬理学における技術の進歩
  • 市場抑制要因分析
    • 厳格な規制ガイドライン
    • 特許医薬品の有効期限
    • 化学療法に伴う合併症
  • 2022年の普及と成長の見通しマッピング
  • 事業環境分析
    • SWOT分析：要因別（政治・法律、経済・技術）
    • ポーターのファイブフォース分析
  • COVID-19の影響分析

第4章 治療法ビジネス分析

  • 乳がん治療薬市場：治療法変動分析
  • 標的療法
    • 乳がん治療薬市場、標的療法、2018～2030年（100万米ドル）
    • アベマシクリブ
    • Ado-トラスツズマブエムタンシン
    • エベロリムス
    • トラスツズマブ
    • リボシクリブ
    • パルボシクリブ
    • ペルツズマブ
    • オラパリブ
    • その他
  • ホルモン療法
    • 乳がん治療薬市場、ホルモン療法、2018年～2030年（100万米ドル）
    • 選択的エストロゲン受容体モジュレーター（Serms）
    • アロマターゼ阻害剤
    • エストロゲン受容体ダウンレギュレーター（Erds）
  • 化学療法
    • 乳がん治療薬市場、化学療法、2018～2030年（100万米ドル）
  • 免疫療法
    • 乳がん治療薬市場、免疫療法、2018年～2030年（100万米ドル）

第5章 がんタイプのビジネス分析

  • 乳がん治療薬市場：がんタイプの変動分析
  • ホルモン受容体
    • 乳がん治療薬市場、ホルモン受容体、2018～2030年（100万米ドル）
  • 彼女2+
    • 乳がん治療薬市場、HER2+、2018-2030（100万米ドル）

第6章 流通チャネルのビジネス分析

  • 乳がん治療薬市場：流通チャネルの変動分析
  • 病院薬局
    • 乳がん治療薬市場、病院薬局、2018年～2030年（100万米ドル）
  • 小売薬局
    • 乳がん治療薬市場、小売薬局、2018～2030年（100万米ドル）
  • その他
    • 乳がん治療薬市場、その他、2018-2030（100万米ドル）

第7章 地域ビジネス分析

  • 地域別の乳がん治療薬市場シェア、2022年および2030年
  • 北米
    • SWOT分析
    • 北米の乳がん治療薬市場、治療法別、2018～2030年（100万米ドル）
    • 北米の乳がん治療薬市場、がんタイプ別、2018～2030年（100万米ドル）
    • 北米の乳がん治療薬市場、流通チャネル別、2018～2030年（100万米ドル）
    • 米国
    • カナダ
  • 欧州
    • SWOT分析
    • 欧州の乳がん治療薬市場、治療法別、2018年～2030年（100万米ドル）
    • 欧州の乳がん治療薬市場、がんタイプ別、2018年～2030年（100万米ドル）
    • 欧州の乳がん治療薬市場、流通チャネル別、2018年～2030年（100万米ドル）
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋地域
    • SWOT分析
    • アジア太平洋地域の乳がん治療薬市場、治療法別、2018～2030年（100万米ドル）
    • アジア太平洋地域の乳がん治療薬市場、がんタイプ別、2018～2030年（100万米ドル）
    • アジア太平洋地域の乳がん治療薬市場、流通チャネル別、2018年～2030年（100万米ドル）
    • 日本
    • 中国
    • インド
    • 韓国
    • オーストラリア
    • タイ
  • ラテンアメリカ
    • SWOT分析
    • ラテンアメリカの乳がん治療薬市場、治療法別、2018～2030年（100万米ドル）
    • ラテンアメリカの乳がん治療薬市場、がんタイプ別、2018～2030年（100万米ドル）
    • ラテンアメリカの乳がん治療薬市場、流通チャネル別、2018～2030年（100万米ドル）
    • ブラジル
    • メキシコ
    • アルゼンチン
  • MEA
    • SWOT分析
    • MEAの乳がん治療薬市場、治療法別、2018年～2030年（100万米ドル）
    • MEAの乳がん治療薬市場、がんタイプ別、2018年～2030年（100万米ドル）
    • MEAの乳がん治療薬市場、流通チャネル別、2018年～2030年（100万米ドル）
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第8章 競合情勢

  • 会社分類
  • 戦略マッピング
    • 新製品の発売
    • パートナーシップ
    • 取得
    • コラボレーション
    • 資金調達
  • 企業の市場シェア分析、2022年
  • 企業プロファイル
    • Novartis Ag
    • Pfizer, Inc
    • Merck Kgaa
    • Janssen Pharmaceuticals, Inc.
    • Celgene Corporation, Inc.
    • Genzyme Corporation
    • F. Hoffmann-La Roche Ltd
    • Astrazeneca
    • Abbvie Inc.
    • Bristol-Myers Squibb Company
    • Macrogenics, Inc.
    • Celldex Therapeutics
    • Onyx Pharmaceuticals Inc.

第9章 結論

図表

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Breast Cancer Drugs Market, by Region, 2018 - 2030 (USD Million)
  • Table 4 Global Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 5 Global Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 6 Global Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 7 North America Breast Cancer Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 8 North America Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 9 North America Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 10 North America Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 11 U.S. Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 12 U.S. Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 13 U.S. Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 14 Canada Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 15 Canada Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 16 Canada Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 17 Canada Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 18 Canada Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 19 Europe Breast Cancer Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 20 Europe Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 21 Europe Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 22 Europe Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 23 Germany Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 24 Germany Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 25 Germany Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 26 UK Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 27 UK Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 28 UK Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 29 France Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 30 France Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 31 France Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 32 Italy Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 33 Italy Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 34 Italy Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 35 Spain Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 36 Spain Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 37 Spain Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 38 Denmark Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 39 Denmark Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 40 Denmark Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 41 Sweden Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 42 Sweden Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 43 Sweden Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 44 Norway Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 45 Norway Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 46 Norway Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific Breast Cancer Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 51 China Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 52 China Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 53 China Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 54 Japan Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 55 Japan Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 56 Japan Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 57 India Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 58 India Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 59 India Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 60 South Korea Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 61 South Korea Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 62 South Korea Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 63 Australia Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 64 Australia Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 65 Australia Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 66 Thailand Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 67 Thailand Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 68 Thailand Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 69 Latin America Breast Cancer Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 70 Latin America Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 71 Latin America Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 72 Latin America Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 73 Brazil Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 74 Brazil Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 75 Brazil Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 76 Mexico Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 77 Mexico Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 78 Mexico Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 79 Argentina Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 80 Argentina Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 81 Argentina Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa Breast Cancer Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 83 Middle East & Africa Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 84 Middle East & Africa Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 85 Middle East & Africa Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 86 South Africa Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 87 South Africa Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 88 South Africa Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 89 Saudi Arabia Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 90 Saudi Arabia Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 91 Saudi Arabia Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 92 UAE Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 93 UAE Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 94 UAE Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 95 Kuwait Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 96 Kuwait Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 97 Kuwait Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 98 Financial performance
  • Table 99 Key companies undergoing expansions
  • Table 100 Key companies undergoing acquisitions
  • Table 101 Key companies undergoing collaborations
  • Table 102 Key companies launching new products/services
  • Table 103 Key companies undergoing partnerships
  • Table 104 Key companies undertaking other strategies

List of Figures

  • Fig. 1 Information Procurement
  • Fig. 2 Primary Research Pattern
  • Fig. 3 Market Research Approaches
  • Fig. 4 Value Chain-Based Sizing & Forecasting
  • Fig. 5 Market Formulation & Validation
  • Fig. 6 Breast Cancer Drugs Market Segmentation
  • Fig. 7 Market Snapshot, 2022
  • Fig. 8 Market Trends & Outlook
  • Fig. 9 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 10 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 11 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 13 Porter's Five Forces Analysis
  • Fig. 14 Market Penetration Vs Growth Prospect Mapping, 2022
  • Fig. 15 Global Breast Cancer Drugs: By Therapy, Movement Analysis
  • Fig. 16 Global Breast Cancer Drugs Market, for Targeted Therapy, 2018 - 2030 (USD Million)
  • Fig. 17 Global Breast Cancer Drugs Market, for Abemaciclib, 2018 - 2030 (USD Million)
  • Fig. 18 Global Breast Cancer Drugs Market, for Ado-Trastuzumab Emtansine, 2018 - 2030 (USD Million)
  • Fig. 19 Global Breast Cancer Drugs Market, for Everolimus, 2018 - 2030 (USD Million)
  • Fig. 20 Global Breast Cancer Drugs Market, for Trastuzumab, 2018 - 2030 (USD Million)
  • Fig. 21 Global Breast Cancer Drugs Market, for Ribociclib2 018 - 2030 (USD Million)
  • Fig. 22 Global Breast Cancer Drugs Market, for Palbociclib, 2018 - 2030 (USD Million)
  • Fig. 23 Global Breast Cancer Drugs Market, for Pertuzumab, 2018 - 2030 (USD Million)
  • Fig. 24 Global Breast Cancer Drugs Market, for Olaparib, 2018 - 2030 (USD Million)
  • Fig. 25 Global Breast Cancer Drugs Market, for Others, 2018 - 2030 (USD Million)
  • Fig. 26 Global Breast Cancer Drugs Market, for Hormonal Therapy, 2018 - 2030 (USD Million)
  • Fig. 27 Global Breast Cancer Drugs Market, for Selective Estrogen Receptor Modulators (SERMs), 2018 - 2030 (USD Million)
  • Fig. 28 Global Breast Cancer Drugs Market, for Aromatase Inhibitors, 2018 - 2030 (USD Million)
  • Fig. 29 Global Breast Cancer Drugs Market, for Estrogen Receptor Down regulators (ERDs), 2018 - 2030 (USD Million)
  • Fig. 30 Global Breast Cancer Drugs Market, for Chemotherapy, 2018 - 2030 (USD Million)
  • Fig. 31 Global Breast Cancer Drugs Market, for Immunotherapy, 2018 - 2030 (USD Million)
  • Fig. 32 Global Breast Cancer Drugs: Cancer Type, Movement Analysis
  • Fig. 33 Global Breast Cancer Drugs Market, for Hormone Receptor, 2018 - 2030 (USD Million)
  • Fig. 34 Global Breast Cancer Drugs Market, for HER2+, 2018 - 2030 (USD Million)
  • Fig. 35 Global Breast Cancer Drugs: Distribution Channel, Movement Analysis
  • Fig. 36 Global Breast Cancer Drugs Market, for Hospital Pharmacies, 2018 - 2030 (USD Million)
  • Fig. 37 Global Breast Cancer Drugs Market, for Retail Pharmacies, 2018 - 2030 (USD Million)
  • Fig. 38 Global Breast Cancer Drugs Market, for Others2018 - 2030 (USD Million)
  • Fig. 39 Regional Marketplace: Key Takeaways Breast Cancer Drugs Market,
  • Fig. 40 Regional Outlook, 2022 & 2030 Breast Cancer Drugs Market,
  • Fig. 41 Global Breast Cancer Drugs Market, Region Movement Analysis
  • Fig. 42 North America Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 43 U.S. Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 44 Canada Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 45 Europe Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 46 Germany Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 47 UK Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 48 France Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 49 Italy Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 50 Spain Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 51 Denmark Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 52 Sweden Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 53 Norway Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 54 Asia Pacific Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 55 Japan Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 56 China Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 57 India Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 58 Australia Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 59 South Korea Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 60 Thailand Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 61 Latin America Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 62 Brazil Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 63 Mexico Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 64 Argentina Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 65 Middle East and Africa Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 66 South Africa Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 67 Saudi Arabia Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 68 UAE Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 69 Kuwait Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
目次
Product Code: GVR-3-68038-041-5

Breast Cancer Drugs Market Growth & Trends

The global breast cancer drugs market size is expected to reach USD 58.69 billion by 2030, registering a CAGR of 9.09% from 2023 to 2030, according to a new report by Grand View Research, Inc. The growth is majorly attributed to the rising disease prevalence, increasing R&D investments, and initiatives by prominent players. Moreover, the trend towards personalized medicine, which involves tailoring treatment for individual patients based on their genetic makeup, is driving the growth of the market. Advances in genomics and molecular biology have led to the development of targeted therapies, which are more effective and have fewer side effects than traditional chemotherapy. Governments around the world are investing in the research and development of new drugs and treatment options. For instance, the U.S.

National Cancer Institute has established several research programs to develop new drugs and improve the efficacy of existing treatments. Similarly, in January 2023, the Australian government announced an investment of USD 16.01 million in developing targeted treatments for women. The investment is expected to fund 23 projects including research on breast cancer through a grant program by the National Health and Medical Research Council. The increasing participation of non-profit organizations is anticipated to propel the market growth. For instance, in June 2022, Susan G. Komen, a breast cancer organization, announced to receive USD 21 million to support around 48 research projects at 26 academic institutions. The majority of funds are allocated to research on aggressive breast cancers, followed by clinical trials and research on eliminating the disparities in the market.

Furthermore, breast cancer patients have been affected by the pandemic as the risk of complications from COVID-19 increases due to their weakened immune systems. As a result, many patients had to postpone or cancel their treatments, which affected the demand for drugs. Moreover, the economic impact of the pandemic also affected the market. The loss of employment or deduction in the income level impacted the affordability of drugs. This, in turn, resulted in reduced product demand and short to medium-term effects on the market. The cost of drugs has a significant impact on the market. High drug prices can limit their usage and affect demand, while lower prices can increase accessibility and demand. Thus, stakeholders need to balance the need for affordable drugs with the need for continued R&D to improve treatment options.

Breast Cancer Drugs Market Report Highlights

  • The immunotherapy type segment was one of the fastest-growing areas of therapy in the market in 2022. Immunotherapy works by stimulating the patient's immune system to recognize and attack cancer cells. This approach has shown promising results in a variety of types, including breast cancer
  • By type, the hormone receptor segment captured the majority of the market share in 2022. Hormone receptor-positive breast cancer is the most common subtype. As a result, hormone therapy drugs have been a mainstay of treatment
  • The hospital pharmacies distribution channel segment held the largest share in 2022. Hospital pharmacies often have access to a wide range of specialized drugs and therapies as compared to retail pharmacies or other channels
  • In terms of revenue share, North America had a dominant position in the global industry in 2022 owing to the increased prevalence of breast cancer, high healthcare expenditures, and ongoing R&D activities

Table of Contents

Chapter 1. Methodology And Scope

  • 1.1 Market Segmentation
  • 1.2 Market Definitions And Objectives
    • 1.2.1 Objective - 1
    • 1.2.2 Objective - 2
    • 1.2.3 Objective - 3
  • 1.3 Research Methodology
  • 1.4 Information Procurement
    • 1.4.1 Purchased Database
    • 1.4.2 Gvr's Internal Database
    • 1.4.3 Secondary Sources
    • 1.4.4 Primary Research
  • 1.5 Information Or Data Analysis
    • 1.5.1 Data Analysis Models
  • 1.6 Market Formulation & Validation
  • 1.7 Model Details
    • 1.7.1 Commodity Flow Analysis
  • 1.8 List Of Secondary Sources
  • 1.9 List Of Abbreviations
  • 1.10 List Of Primary Sources

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Therapy And Cancer Type Snapshot
  • 2.3. Distribution Channel Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation And Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Trends And Outlook
  • 3.4. Market Dynamics
    • 3.4.1. Increased Incidence And Prevalence Rate Of Cancer Worldwide
    • 3.4.2. High Investment In R&D
    • 3.4.3. Technological Advancement In Cancer Biology & Pharmacology
  • 3.5. Market Restraint Analysis
    • 3.5.1. Stringent Regulatory Guidelines
    • 3.5.2. Expiry Of Patented Drugs
    • 3.5.3. Complications Associated With Chemotherapy
  • 3.6. Penetration And Growth Prospect Mapping 2022
  • 3.7. Business Environment Analysis
    • 3.7.1. Swot Analysis; By Factor (Political & Legal, Economic And Technological)
    • 3.7.2. Porter's Five Forces Analysis
  • 3.8. Covid-19 Impact Analysis

Chapter 4. Therapy Business Analysis

  • 4.1. Breast Cancer Drugs Market: Therapy Movement Analysis
  • 4.2. Targeted Therapy
    • 4.2.1. Breast Cancer Drugs Market, Targeted Therapy, 2018 - 2030 (USD Million)
    • 4.2.2. Abemaciclib
      • 4.2.2.1. Breast Cancer Drugs Market, Abemaciclib, 2018 - 2030 (USD Million)
    • 4.2.3. Ado-Trastuzumab Emtansine
      • 4.2.3.1. Breast Cancer Drugs Market, Ado-Trastuzumab Emtansine, 2018 - 2030 (USD Million)
    • 4.2.4. Everolimus
      • 4.2.4.1. Breast Cancer Drugs Market, Everolimus, 2018 - 2030 (USD Million)
    • 4.2.5. Trastuzumab
      • 4.2.5.1. Breast Cancer Drugs Market, Trastuzumab, 2018 - 2030 (USD Million)
    • 4.2.6. Ribociclib
      • 4.2.6.1. Breast Cancer Drugs Market, Ribociclib, 2018 - 2030 (USD Million)
    • 4.2.7. Palbociclib
      • 4.2.7.1. Breast Cancer Drugs Market, Palbociclib, 2018 - 2030 (USD Million)
    • 4.2.8. Pertuzumab
      • 4.2.8.1. Breast Cancer Drugs Market, Pertuzumab, 2018 - 2030 (USD Million)
    • 4.2.9. Olaparib
      • 4.2.9.1. Breast Cancer Drugs Market, Olaparib, 2018 - 2030 (USD Million)
    • 4.2.10. Others
      • 4.2.10.1. Breast Cancer Drugs Market, Others, 2018 - 2030 (USD Million)
  • 4.3. Hormonal Therapy
    • 4.3.1. Breast Cancer Drugs Market, Hormonal Therapy, 2018 - 2030 (USD Million)
    • 4.3.2. Selective Estrogen Receptor Modulators (Serms)
      • 4.3.2.1. Breast Cancer Drugs Market, Selective Estrogen Receptor Modulators (Serms), 2018 - 2030 (USD Million)
    • 4.3.3. Aromatase Inhibitors
      • 4.3.3.1. Breast Cancer Drugs Market, Aromatase Inhibitors, 2018 - 2030 (USD Million)
    • 4.3.4. Estrogen Receptor Down Regulators (Erds)
      • 4.3.4.1. Breast Cancer Drugs Market, Estrogen Receptor Down Regulators (Erds), 2018 - 2030 (USD Million)
  • 4.4. Chemotherapy
    • 4.4.1. Breast Cancer Drugs Market, Chemotherapy, 2018 - 2030 (USD Million)
  • 4.5. Immunotherapy
    • 4.5.1. Breast Cancer Drugs Market, Immunotherapy, 2018 - 2030 (USD Million)

Chapter 5. Cancer Type Business Analysis

  • 5.1. Breast Cancer Drugs Market: Cancer Type Movement Analysis
  • 5.2. Hormone Receptor
    • 5.2.1. Breast Cancer Drugs Market, Hormone Receptor, 2018 - 2030 (USD Million)
  • 5.3. Her2+
    • 5.3.1. Breast Cancer Drugs Market, Her2+, 2018 - 2030 (USD Million)

Chapter 6. Distribution Channel Business Analysis

  • 6.1. Breast Cancer Drugs Market: Distribution Channel Movement Analysis
  • 6.2. Hospital Pharmacies
    • 6.2.1. Breast Cancer Drugs Market, Hospital Pharmacies, 2018 - 2030 (USD Million)
  • 6.3. Retail Pharmacies
    • 6.3.1. Breast Cancer Drugs Market, Retail Pharmacies, 2018 - 2030 (USD Million)
  • 6.4. Others
    • 6.4.1. Breast Cancer Drugs Market, Others, 2018 - 2030 (USD Million)

Chapter 7. Regional Business Analysis

  • 7.1. Breast Cancer Drugs Market Share By Region, 2022 & 2030
  • 7.2. North America
    • 7.2.1. Swot Analysis
    • 7.2.2. North America Breast Cancer Drugs Market, By Therapy, 2018 - 2030 (USD Million)
    • 7.2.3. North America Breast Cancer Drugs Market, By Cancer Type, 2018 - 2030 (USD Million)
    • 7.2.4. North America Breast Cancer Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
    • 7.2.5. U.S.
      • 7.2.5.1. Key Country Dynamics
      • 7.2.5.2. Target Disease Prevalence
      • 7.2.5.3. Competitive Scenario
      • 7.2.5.4. Regulatory Framework
      • 7.2.5.5. Reimbursement Scenario
      • 7.2.5.6. U.S. Breast Cancer Drugs Market 2018 - 2030 (USD Million)
    • 7.2.6. Canada
      • 7.2.6.1. Key Country Dynamics
      • 7.2.6.2. Target Disease Prevalence
      • 7.2.6.3. Competitive Scenario
      • 7.2.6.4. Regulatory Framework
      • 7.2.6.5. Reimbursement Scenario
      • 7.2.6.6. Canada Breast Cancer Drugs Market 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Swot Analysis
    • 7.3.2. Europe Breast Cancer Drugs Market, By Therapy, 2018 - 2030 (USD Million)
    • 7.3.3. Europe Breast Cancer Drugs Market, By Cancer Type, 2018 - 2030 (USD Million)
    • 7.3.4. Europe Breast Cancer Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
    • 7.3.5. Germany
      • 7.3.5.1. Key Country Dynamics
      • 7.3.5.2. Target Disease Prevalence
      • 7.3.5.3. Competitive Scenario
      • 7.3.5.4. Regulatory Framework
      • 7.3.5.5. Reimbursement Scenario
      • 7.3.5.6. Germany Breast Cancer Drugs Market 2018 - 2030 (USD Million)
    • 7.3.6. Uk
      • 7.3.6.1. Key Country Dynamics
      • 7.3.6.2. Target Disease Prevalence
      • 7.3.6.3. Competitive Scenario
      • 7.3.6.4. Regulatory Framework
      • 7.3.6.5. Reimbursement Scenario
      • 7.3.6.6. Uk Breast Cancer Drugs Market 2018 - 2030 (USD Million)
    • 7.3.7. France
      • 7.3.7.1. Key Country Dynamics
      • 7.3.7.2. Target Disease Prevalence
      • 7.3.7.3. Competitive Scenario
      • 7.3.7.4. Regulatory Framework
      • 7.3.7.5. Reimbursement Scenario
      • 7.3.7.6. France Breast Cancer Drugs Market 2018 - 2030 (USD Million)
    • 7.3.8. Italy
      • 7.3.8.1. Key Country Dynamics
      • 7.3.8.2. Target Disease Prevalence
      • 7.3.8.3. Competitive Scenario
      • 7.3.8.4. Regulatory Framework
      • 7.3.8.5. Reimbursement Scenario
      • 7.3.8.6. Italy Breast Cancer Drugs Market 2018 - 2030 (USD Million)
    • 7.3.9. Spain
      • 7.3.9.1. Key Country Dynamics
      • 7.3.9.2. Target Disease Prevalence
      • 7.3.9.3. Competitive Scenario
      • 7.3.9.4. Regulatory Framework
      • 7.3.9.5. Reimbursement Scenario
      • 7.3.9.6. Spain Breast Cancer Drugs Market 2018 - 2030 (USD Million)
    • 7.3.10. Denmark
      • 7.3.10.1. Key Country Dynamics
      • 7.3.10.2. Target Disease Prevalence
      • 7.3.10.3. Competitive Scenario
      • 7.3.10.4. Regulatory Framework
      • 7.3.10.5. Reimbursement Scenario
      • 7.3.10.6. Denmark Breast Cancer Drugs Market 2018 - 2030 (USD Million)
    • 7.3.11. Sweden
      • 7.3.11.1. Key Country Dynamics
      • 7.3.11.2. Target Disease Prevalence
      • 7.3.11.3. Competitive Scenario
      • 7.3.11.4. Regulatory Framework
      • 7.3.11.5. Reimbursement Scenario
      • 7.3.11.6. Sweden Breast Cancer Drugs Market 2018 - 2030 (USD Million)
    • 7.3.12. Norway
      • 7.3.12.1. Key Country Dynamics
      • 7.3.12.2. Target Disease Prevalence
      • 7.3.12.3. Competitive Scenario
      • 7.3.12.4. Regulatory Framework
      • 7.3.12.5. Reimbursement Scenario
      • 7.3.12.6. Norway Breast Cancer Drugs Market 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Swot Analysis
    • 7.4.2. Asia Pacific Breast Cancer Drugs Market, By Therapy, 2018 - 2030 (USD Million)
    • 7.4.3. Asia Pacific Breast Cancer Drugs Market, By Cancer Type, 2018 - 2030 (USD Million)
    • 7.4.4. Asia Pacific Breast Cancer Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
    • 7.4.5. Japan
      • 7.4.5.1. Key Country Dynamics
      • 7.4.5.2. Target Disease Prevalence
      • 7.4.5.3. Competitive Scenario
      • 7.4.5.4. Regulatory Framework
      • 7.4.5.5. Reimbursement Scenario
      • 7.4.5.6. Japan Breast Cancer Drugs Market 2018 - 2030 (USD Million)
    • 7.4.6. China
      • 7.4.6.1. Key Country Dynamics
      • 7.4.6.2. Target Disease Prevalence
      • 7.4.6.3. Competitive Scenario
      • 7.4.6.4. Regulatory Framework
      • 7.4.6.5. Reimbursement Scenario
      • 7.4.6.6. China Breast Cancer Drugs Market 2018 - 2030 (USD Million)
    • 7.4.7. India
      • 7.4.7.1. Key Country Dynamics
      • 7.4.7.2. Target Disease Prevalence
      • 7.4.7.3. Competitive Scenario
      • 7.4.7.4. Regulatory Framework
      • 7.4.7.5. Reimbursement Scenario
      • 7.4.7.6. India Breast Cancer Drugs Market 2018 - 2030 (USD Million)
    • 7.4.8. South Korea
      • 7.4.8.1. Key Country Dynamics
      • 7.4.8.2. Target Disease Prevalence
      • 7.4.8.3. Competitive Scenario
      • 7.4.8.4. Regulatory Framework
      • 7.4.8.5. Reimbursement Scenario
      • 7.4.8.6. South Korea Breast Cancer Drugs Market 2018 - 2030 (USD Million)
    • 7.4.9. Australia
      • 7.4.9.1. Key Country Dynamics
      • 7.4.9.2. Target Disease Prevalence
      • 7.4.9.3. Competitive Scenario
      • 7.4.9.4. Regulatory Framework
      • 7.4.9.5. Reimbursement Scenario
      • 7.4.9.6. Australia Breast Cancer Drugs Market 2018 - 2030 (USD Million)
    • 7.4.10. Thailand
      • 7.4.10.1. Key Country Dynamics
      • 7.4.10.2. Target Disease Prevalence
      • 7.4.10.3. Competitive Scenario
      • 7.4.10.4. Regulatory Framework
      • 7.4.10.5. Reimbursement Scenario
      • 7.4.10.6. Thailand Breast Cancer Drugs Market 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Swot Analysis
    • 7.5.2. Latin America Breast Cancer Drugs Market, By Therapy, 2018 - 2030 (USD Million)
    • 7.5.3. Latin America Breast Cancer Drugs Market, By Cancer Type, 2018 - 2030 (USD Million)
    • 7.5.4. Latin America Breast Cancer Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
    • 7.5.5. Brazil
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Target Disease Prevalence
      • 7.5.5.3. Competitive Scenario
      • 7.5.5.4. Regulatory Framework
      • 7.5.5.5. Reimbursement Scenario
      • 7.5.5.6. Brazil Breast Cancer Drugs Market 2018 - 2030 (USD Million)
    • 7.5.6. Mexico
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Target Disease Prevalence
      • 7.5.6.3. Competitive Scenario
      • 7.5.6.4. Regulatory Framework
      • 7.5.6.5. Reimbursement Scenario
      • 7.5.6.6. Mexico Breast Cancer Drugs Market 2018 - 2030 (USD Million)
    • 7.5.7. Argentina
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Target Disease Prevalence
      • 7.5.7.3. Competitive Scenario
      • 7.5.7.4. Regulatory Framework
      • 7.5.7.5. Reimbursement Scenario
      • 7.5.7.6. Argentina Breast Cancer Drugs Market 2018 - 2030 (USD Million)
  • 7.6. MEA
    • 7.6.1. Swot Analysis
    • 7.6.2. MEA Breast Cancer Drugs Market, By Therapy, 2018 - 2030 (USD Million)
    • 7.6.3. MEA Breast Cancer Drugs Market, By Cancer Type, 2018 - 2030 (USD Million)
    • 7.6.4. MEA Breast Cancer Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
    • 7.6.5. South Africa
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Target Disease Prevalence
      • 7.6.5.3. Competitive Scenario
      • 7.6.5.4. Regulatory Framework
      • 7.6.5.5. Reimbursement Scenario
      • 7.6.5.6. South Africa Breast Cancer Drugs Market 2018 - 2030 (USD Million)
    • 7.6.6. Saudi Arabia
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Target Disease Prevalence
      • 7.6.6.3. Competitive Scenario
      • 7.6.6.4. Regulatory Framework
      • 7.6.6.5. Reimbursement Scenario
      • 7.6.6.6. Saudi Arabia Breast Cancer Drugs Market 2018 - 2030 (USD Million)
    • 7.6.7. UAE
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Target Disease Prevalence
      • 7.6.7.3. Competitive Scenario
      • 7.6.7.4. Regulatory Framework
      • 7.6.7.5. Reimbursement Scenario
      • 7.6.7.6. UAE Breast Cancer Drugs Market 2018 - 2030 (USD Million)
    • 7.6.8. Kuwait
      • 7.6.8.1. Key Country Dynamics
      • 7.6.8.2. Target Disease Prevalence
      • 7.6.8.3. Competitive Scenario
      • 7.6.8.4. Regulatory Framework
      • 7.6.8.5. Reimbursement Scenario
      • 7.6.8.6. Kuwait Breast Cancer Drugs Market 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1 Company Categorization
  • 8.2 Strategy Mapping
    • 8.2.1 New Product Launch
    • 8.2.2 Partnerships
    • 8.2.3 Acquisition
    • 8.2.4 Collaboration
    • 8.2.5 Funding
  • 8.3 Company Market Share Analysis, 2022
  • 8.4 Company Profiles
    • 8.4.1 Novartis Ag
      • 8.4.1.1 Company Overview
      • 8.4.1.2 Financial Performance
      • 8.4.1.3 Product Benchmarking
      • 8.4.1.4 Strategic Initiatives
    • 8.4.2 Pfizer, Inc
      • 8.4.2.1 Company Overview
      • 8.4.2.2 Financial Performance
      • 8.4.2.3 Product Benchmarking
      • 8.4.2.4 Strategic Initiatives
    • 8.4.3 Merck Kgaa
      • 8.4.3.1 Company Overview
      • 8.4.3.2 Financial Performance
      • 8.4.3.3 Product Benchmarking
      • 8.4.3.4 Strategic Initiatives
    • 8.4.4 Janssen Pharmaceuticals, Inc.
      • 8.4.4.1 Company Overview
      • 8.4.4.2 Financial Performance
      • 8.4.4.3 Product Benchmarking
      • 8.4.4.4 Strategic Initiatives
    • 8.4.5 Celgene Corporation, Inc.
      • 8.4.5.1 Company Overview
      • 8.4.5.2 Financial Performance
      • 8.4.5.3 Product Benchmarking
      • 8.4.5.4 Strategic Initiatives
    • 8.4.6 Genzyme Corporation
      • 8.4.6.1 Company Overview
      • 8.4.6.2 Financial Performance
      • 8.4.6.3 Product Benchmarking
      • 8.4.6.4 Strategic Initiatives
    • 8.4.7 F. Hoffmann-La Roche Ltd
      • 8.4.7.1 Company Overview
      • 8.4.7.2 Financial Performance
      • 8.4.7.3 Product Benchmarking
      • 8.4.7.4 Strategic Initiatives
    • 8.4.8 Astrazeneca
      • 8.4.8.1 Company Overview
      • 8.4.8.2 Financial Performance
      • 8.4.8.3 Product Benchmarking
      • 8.4.8.4 Strategic Initiatives
    • 8.4.9 Abbvie Inc.
      • 8.4.9.1 Company Overview
      • 8.4.9.2 Financial Performance
      • 8.4.9.3 Product Benchmarking
      • 8.4.9.4 Strategic Initiatives
    • 8.4.10 Bristol-Myers Squibb Company
      • 8.4.10.1 Company Overview
      • 8.4.10.2 Financial Performance
      • 8.4.10.3 Product Benchmarking
      • 8.4.10.4 Strategic Initiatives
    • 8.4.11 Macrogenics, Inc.
      • 8.4.11.1 Company Overview
      • 8.4.11.2 Financial Performance
      • 8.4.11.3 Product Benchmarking
      • 8.4.11.4 Strategic Initiatives
    • 8.4.12 Celldex Therapeutics
      • 8.4.12.1 Company Overview
      • 8.4.12.2 Financial Performance
      • 8.4.12.3 Product Benchmarking
      • 8.4.12.4 Strategic Initiatives
    • 8.4.13 Onyx Pharmaceuticals Inc.
      • 8.4.13.1 Company Overview
      • 8.4.13.2 Financial Performance
      • 8.4.13.3 Product Benchmarking
      • 8.4.13.4 Strategic Initiatives

Chapter 9 Conclusion